Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis (Q38439813)
Jump to navigation
Jump to search
scientific article published on 24 April 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis |
scientific article published on 24 April 2015 |
Statements
1 reference
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis (English)
1 reference
Sonya J Snedecor
1 reference
Christina Howlett
1 reference
Daniel J Landsburg
1 reference
Jakub Svoboda
1 reference
Elise A Chong
1 reference
Stephen J Schuster
1 reference
Sunita Dwivedy Nasta
1 reference
Tatyana Feldman
1 reference
Allison Rago
1 reference
Kristy M Walsh
1 reference
Scott Weber
1 reference
Andre Goy
1 reference
Anthony Mato
1 reference
24 April 2015
1 reference
1 reference
Identifiers
1 reference